pyrazines has been researched along with gilteritinib in 101 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 26 (25.74) | 24.3611 |
2020's | 75 (74.26) | 2.80 |
Authors | Studies |
---|---|
Thom, C | 1 |
Stein, EM | 1 |
Hernandez, D; Lee, LY; Levis, M; Nguyen, B; Rajkhowa, T; Raman, JR; Small, D; Smith, SC | 1 |
Kaneko, N; Kuromitsu, S; Mori, K; Mori, M; Saito, R; Shimada, I; Tanaka, R; Ueno, Y; Yamada, M | 1 |
Altman, JK; Baer, MR; Bahceci, E; Claxton, D; Cortes, J; Erba, HP; Gill, S; Goldberg, S; Jurcic, JG; Larson, RA; Levis, M; Litzow, M; Liu, C; Martinelli, G; Neubauer, A; Perl, AE; Ritchie, E; Röllig, C; Schiller, G; Smith, C; Spira, AI; Strickland, SA; Stuart, R; Tibes, R; Ustun, C; Wang, ES | 1 |
Sheridan, C | 1 |
Burthem, J; Gorcea, CM; Tholouli, E | 1 |
Bahceci, E; Iida, H; Kaneko, M; Kobayashi, Y; Kusano, M; Miyamoto, T; Miyawaki, S; Morita, S; Naoe, T; Sakura, T; Takeshita, S; Usuki, K; Yamada, S | 1 |
Ai, J; Dai, Y; Gu, W; Ji, Y; Song, Z; Wang, Y; Xing, L; Ye, J | 1 |
Dhillon, S | 1 |
Tiong, IS; Wei, AH | 1 |
Canaani, J; Carroll, M; McMahon, CM; Morrissette, JJD; Perl, AE; Qualtieri, JN; Rea, B; Sargent, RL; Watt, CD | 1 |
Perl, AE | 2 |
Bixby, DL; Marini, BL; Perissinotti, AJ; Weis, TM | 1 |
Estey, EH; Percival, MM | 1 |
Adamia, S; Buhrlage, SJ; Case, AE; Dubreuil, P; Gokhale, PC; Gray, N; Griffin, JD; Letard, S; Liu, X; Meng, C; Sattler, M; Stone, RM; Tiv, HL; Wang, J; Weisberg, E; Yang, J | 1 |
Dzinic, SH; Edwards, H; Ge, Y; Knight, T; Kushner, J; Lin, H; Ma, J; Polin, L; Qiao, X; Taub, JW; Wang, G; Wang, Y; White, K; Zhao, L; Zhao, S | 1 |
Saleh, N | 1 |
Eskazan, AE; Kucukyurt, S | 1 |
Akahane, D; Fujimoto, H; Gotoh, A; Katagiri, S; Moriyama, M; Yoshizawa, S | 1 |
Baer, MR; Bahceci, E; Berman, E; Chou, WC; Ciceri, F; Cortes, JE; Di Stasi, A; Erba, HP; Fabbiano, F; Fathi, AT; Hasabou, N; Hosono, N; Kasner, M; Larson, RA; Lee, JH; Levis, MJ; Liu, C; Liu, X; Martinelli, G; Montesinos, P; Neubauer, A; Olin, R; Paolini, S; Pardee, T; Perl, AE; Podoltsev, N; Recher, C; Stuart, R; Ustun, C; Yokoyama, H; Yoon, SS | 1 |
Sidaway, P | 1 |
DiNardo, CD; Wei, AH | 1 |
Hussain, MJ; Katz, DA; Larson, M; Miller, I; Nathan, S; Ustun, C; Varma, A; Yun, HD | 1 |
Rowe, JM | 1 |
Smith, CC | 1 |
Li, L; Li, M; Li, W; Lin, L | 1 |
Antar, AI; Bazarbachi, A; Jabbour, E; Mohty, M; Otrock, ZK | 1 |
Cerella, C; Christov, C; Diederich, M; Ha, YN; Kijjoa, A; Orlikova-Boyer, B; Song, S | 1 |
Adamia, S; Buhrlage, SJ; Case, AE; Gokhale, PC; Gray, N; Griffin, JD; Liu, X; Meng, C; Sattler, M; Stone, R; Tiv, HL; Wang, J; Weisberg, E; Yang, J | 1 |
Bahceci, E; Hill, JE; Mori, K; Perl, AE; Rahmat, L; Smith, CC; Tarver, TC | 1 |
Lam, SSY; Leung, AYH | 1 |
Burnett, A; Stone, R | 1 |
Aas, IB; Bolstad, B; Dalhus, ML; Enzmann, H; Gisselbrecht, C; Håkonsen, GD; Karpova, N; Lindberg, V; Nilssen, LS; Olsen, HH; Pignatti, F; Rogovska, I; Røshol, H; Tzogani, K; Økvist, M | 1 |
Kim, RS; Shields, CL; Wilde, LR; Yaghy, A | 1 |
Chishaki, R; Ito, T; Kida, M; Kido, M; Kuraoka, K; Kuroda, Y | 1 |
Ando, T; Katsuya, H; Kidoguchi, K; Kimura, S; Kojima, K; Kubota, Y; Kusaba, K; Sano, H; Yamaguchi, K; Yokoo, M; Yoshihara, S | 1 |
Levis, M; Perl, AE | 1 |
Altman, JK; Bahceci, E; James, AJ; Kadokura, T; Levis, MJ; Litzow, M; Liu, C; Lu, Z; Moy, S; Patton, M; Perl, AE; Shepard, D; Smith, CC; Souda, K | 1 |
Elsarrag, RZ; K Keng, M; Pierce, EJ; Reed, DR; Sen, JM | 1 |
Han, H; Hong, J; Kim, D; Kim, H; Koh, Y; Lee, C; Shin, DY; Yoon, SS | 1 |
Arakawa, Y; Fukuoka, K; Hiraki, T; Inoue, K; Isobe, K; Koh, K; Mitani, Y; Mori, M; Noguchi, J; Oshima, K; Sugawa, M; Takaki, T; Tomita, O; Tsumura, Y; Yanagi, M | 1 |
Chen, D; Chen, Z; Wang, Q; Ye, XY | 1 |
Andrews, C; Maze, D; Murphy, T; Sibai, H | 1 |
Naoe, T | 1 |
Baker, R; Chavda, N; Clark, F; Fielding, AK; Gupta, R; Khwaja, A; Kottaridis, P; Mansour, MR; O'Nions, J; Payne, E; Subhan, M; Thomson, K; Troy-Barnes, E; Wilson, AJ | 1 |
Dutta, R; Jeng, MY; Mannis, GN; Tan, IT; Zhang, TY | 1 |
Bever, GJ; Haq, Z; Liu, Y; Pasricha, ND | 1 |
Blair, HA; Kang, C | 1 |
Albors Ferreiro, M; Alonso Vence, N; Antelo Rodríguez, B; Bao Pérez, L; Bello López, JL; Cerchione, C; Cid López, M; Díaz Arias, JÁ; Ferreiro Ferro, R; González Pérez, MS; Martinelli, G; Mosquera Orgueira, A; Mosquera Torre, A; Peleteiro Raíndo, A; Pérez Encinas, MM | 1 |
Abdul-Hamil, NA; Cherchione, C; Martinelli, G; Nagarajan, C; Wong, GC | 1 |
Ballesta-López, O; Martínez-Cuadrón, D; Megías-Vericat, JE; Montesinos, P; Solana-Altabella, A | 1 |
Beaver, L; Blachly, JS; Brinton, LT; Byrd, JC; Canfield, D; Cannon, M; Cempre, C; Govande, M; Harrington, B; Lapalombella, R; Lehman, A; Orwick, S; Sher, S; Skinner, J; Wasmuth, R; Williams, K; Zhang, P | 1 |
Myers, R; Tollkuci, E; Tran, T | 1 |
Fleischmann, M; Heidel, FH; Schnetzke, U; Scholl, S | 1 |
Dobashi, N; Fukushima, R; Gunji, T; Hattori, D; Ishii, H; Ishii, S; Kamitani, I; Katsube, A; Nakano, A; Nishiwaki, K; Oshima, S; Saito, T; Shimada, T; Tanoue, S; Yano, S; Yokoyama, H | 1 |
Hidaka, K; Mori, M | 1 |
Adachi, J; Araki, M; Friboulet, L; Fujita, N; Katayama, K; Katayama, R; Kukimoto-Niino, M; Kutkowska, J; Ma, B; Maruyama, K; Mizuta, H; Nishio, M; Oh-Hara, T; Okada, K; Okuno, Y; Sagae, Y; Sasakura, Y; Shirouzu, M; Simizu, S; Takagi, S; Takemoto, A; Tamai, K; Watanabe, K; Yanagitani, N | 1 |
Fujisawa, S; Harada, S; Izumiyama, K; Kondo, T; Mori, A; Morioka, M; Ogasawara, R; Onozawa, M; Saito, M; Teshima, T | 1 |
De Claro, RA; Farrell, AT; Fu, W; Goldberg, KB; Gudi, R; Norsworthy, KJ; Okusanya, OO; Pazdur, R; Przepiorka, D; Pulte, ED; Qosa, H; Wang, Y; Xu, Q | 1 |
Bottomly, D; Druker, BJ; Joshi, SK; McWeeney, SK; Pittsenbarger, J; Sharzehi, S; Tognon, CE; Traer, E | 1 |
Iwai, F; Kato-Ogura, A; Onaka, T; Otsuka, Y; Yonezawa, A | 1 |
Bagnato, G; Cerchione, C; Giannini, MB; Marconi, G; Martinelli, G; Mosquera Orgueira, A; Musuraca, G; Simonetti, G | 1 |
Aleissa, MM; Alshehri, BS; Gonzalez-Bocco, IH; Leblebjian, H; Luskin, MR; Marty, FM; McDonnell, AM | 1 |
Dzinic, SH; Edwards, H; Ge, Y; Knight, T; Kushner, J; Li, J; Lin, H; Ma, J; Polin, L; Qiao, X; Su, Y; Taub, JW; Wang, G; Wang, J; Wang, L; Wang, Y; White, K | 1 |
Arshad, OA; Babur, O; Bottomly, D; Cendali, F; D'Alessandro, A; Demir, E; Druker, BJ; Fillmore, TL; Gosline, SJC; Gritsenko, MA; Hansen, JR; Hutchinson, C; Joshi, SK; Kaempf, A; Liu, T; McDermott, JE; McWeeney, SK; Moon, J; Nechiporuk, T; Piehowski, PD; Pittsenbarger, J; Reisz, JA; Rodland, KD; Schepmoes, AA; Shi, T; Tognon, CE; Traer, E; Tsai, CF; Tyner, JW; Wang, YT; Watanabe-Smith, K; Weitz, KK | 1 |
Abematsu, T; Iijima-Yamashita, Y; Inaba, Y; Kawano, Y; Kodama, Y; Nakagawa, S; Nishikawa, T; Okamoto, Y; Shiba, N; Takahashi, Y | 1 |
Baker, SD; Garrison, DA; Jin, Y; Sparreboom, A; Uddin, ME | 1 |
Bidet, A; Desplat, V; Dumas, PY; El-Habhab, A; Fernandez, S; Guitart, AV; Leguay, T; Mansier, O; Martineau, D; Massara, L; Pasquet, JM; Pigneux, A; Vigon, I; Villacreces, A | 1 |
Cimino, G; Cipollone, E; Ortu La Barbera, E; Ottone, T; Perrone, S; Scerpa, MC; Siniscalchi, R; Viola, F; Voso, MT | 1 |
Cuglievan, B; Daver, N; DiNardo, C; Kadia, TM; Mahadeo, KM; McCall, D; Nunez, C; Roth, M; Short, NJ; Toepfer, L; Yi, JS | 1 |
Baker, SD; Buelow, DR; Campbell, MJ; Jeon, JY; Pabla, N; Silvaroli, J; Sparreboom, A; Talebi, Z; Zavorka Thomas, ME | 1 |
Garnham, A; Pandya, BJ; Qi, CZ; Shah, MV; Yang, H; Zeidan, AM | 1 |
Jakubik, M; Jastrzębski, K; Kozik, K; Miączyńska, M; Poświata, A; Zdżalik-Bielecka, D | 1 |
Thol, F | 1 |
Atallah, E; Chiba, S; Hasabou, N; Hosono, N; Kim, HJ; Larson, RA; Levis, MJ; Lu, Q; Martinelli, G; Montesinos, P; Neubauer, A; Onozawa, M; Perl, AE; Podoltsev, NA; Récher, C; Schiller, GJ; Sierra, J; Strickland, S; Tiu, R; Wang, ES; Yoon, SS | 1 |
Bahceci, E; Hill, JE; Levis, MJ; Perl, AE; Rosales, M; Smith, CC | 1 |
Chi, S; Harada, S; Izumiyama, K; Kondo, T; Minami, Y; Miyajima, T; Mori, A; Morioka, M; Ogasawara, R; Saito, M; Yokoyama, E | 1 |
Akashi, K; Egashira, N; Hirota, T; Ieiri, I; Miyamoto, T; Suetsugu, K; Tajima, S; Tsuchiya, Y; Yamauchi, T; Yoshimoto, G; Zhang, M | 1 |
Eşkazan, AE; Nuhoğlu Kantarcı, E | 1 |
Guo, MQ; He, YJ; Huang, YX; Li, KX; Li, YH; Pan, WY; Qiu, DZ; Wu, HY; Yang, DH | 1 |
Lee, T; Mitomi, T; Sugamori, H; Yamagishi, C | 1 |
Arrigo, G; Audisio, E; Cerrano, M; D'Ardìa, S; Frairia, C; Freilone, R; Giai, V; Secreto, C; Urbino, I | 1 |
Altman, JK; Chou, WC; Groß-Langenhoff, M; Hasabou, N; Hosono, N; Lee, JH; Levis, MJ; Lu, Q; Martinelli, G; Montesinos, P; Panoskaltsis, N; Perl, AE; Podoltsev, N; Recher, C; Röllig, C; Smith, CC; Strickland, S; Tiu, RV; Yokoyama, H | 1 |
Aumann, S; Canaani, J; Frisch, A; Ganzel, C; Henig, I; Kugler, E; Moshe, Y; Nachmias, B; Ofran, Y; Raanani, P; Ram, R; Shimony, S; Vainstein, V; Wolach, O; Yeshurun, M | 1 |
Kataoka, H; Oka, A; Saita, T; Shin, M; Yamada, M | 1 |
Baker, SD; Bhatnagar, B; Blachly, JS; Blaser, BW; Buelow, DR; Eisenmann, ED; Jeon, JY; Orwick, SJ; Pabla, NS; Stromatt, JC | 1 |
Altman, JK; Chou, WC; Esteve, J; Gambacorti-Passerini, C; Gill, SC; Havelange, V; Heuser, M; Hill, JE; Laribi, K; Lee, JH; Liu, S; Minden, MD; Montesinos, P; Naoe, T; Patkowska, E; Philipose, N; Rich, ES; Tiu, RV; Wang, ES; Watson, AM; Wu, R | 1 |
Fu, J; Gu, A; Peng, J; Xu, Y; Yang, B; Zhou, S | 1 |
Barnett, K; Crews, K; Diedrich, JD; Huang, X; Konopleva, M; Li, Z; Pui, CH; Reyes, N; Savic, D; Smart, B; Wang, P; Wei, CL; Xu, B; Yang, JJ; Yang, W; Yeoh, AEJ; Yoshimura, S; Yu, J; Zhang, J; Zhao, X | 1 |
Ciervo, JR; Derkach, A; King, AC; Ranaghan, CP; Stein, ES; Stump, SE; Weis, TM | 1 |
Aoe, M; Fujiwara, K; Ishida, H; Kanamitsu, K; Nodomi, S; Ochi, M; Tamefusa, K; Tatebe, Y; Washio, K | 1 |
Adachi, S; Akazawa, R; Hiramatsu, H; Kamitori, T; Kato, I; Saida, S; Takeshita, S; Takita, J; Tasaka, K; Uchihara, Y; Umeda, K; Usami, A; Yoshioka, Y | 1 |
Asada, N; Ennishi, D; Fujii, K; Fujii, N; Fujiwara, H; Kondo, K; Kondo, T; Maeda, Y; Matsubara, C; Matsumura, A; Matsuoka, KI; Nishimori, H; Terao, T; Ueda, H | 1 |
Braun, T; Cabannes-Hamy, A; Ghez, D; Goldwirt, L; Jacqz-Aigrain, E; Kelly, L; Kohn, M; Lengline, E; Mourah, S; Puissant, A; Raffoux, E; Rousselot, P; Sauvageon, H; Siavellis, J; Vignal, N | 1 |
Kim, H; Kim, IS | 1 |
Fan, G; Gao, J; Liu, G; Luo, P; Qiu, H; Song, X; Wu, J; Yang, Y | 1 |
25 review(s) available for pyrazines and gilteritinib
Article | Year |
---|---|
Molecularly targeted therapies for acute myeloid leukemia.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Clinical Trials as Topic; Epigenesis, Genetic; fms-Like Tyrosine Kinase 3; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Mutation; Phenylurea Compounds; Piperidines; Proto-Oncogene Proteins c-bcl-2; Pyrazines | 2015 |
ASP2215 in the treatment of relapsed/refractory acute myeloid leukemia with FLT3 mutation: background and design of the ADMIRAL trial.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Protocols; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mice; Protein Kinase Inhibitors; Pyrazines; Recurrence; Research Design | 2018 |
Gilteritinib: First Global Approval.
Topics: Aniline Compounds; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Approval; fms-Like Tyrosine Kinase 3; Humans; Japan; Leukemia, Myeloid, Acute; Lung Neoplasms; Molecular Structure; Mutation; Protein Kinase Inhibitors; Pyrazines; Randomized Controlled Trials as Topic | 2019 |
New drugs creating new challenges in acute myeloid leukemia.
Topics: Aminopyridines; Aniline Compounds; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Pyrazines; Pyridines; Staurosporine; Triazines; United States; United States Food and Drug Administration | 2019 |
Availability of FLT3 inhibitors: how do we use them?
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Benzothiazoles; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Sorafenib; Staurosporine | 2019 |
Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
Topics: Aniline Compounds; Antineoplastic Agents; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrazines; Staurosporine | 2019 |
Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia.
Topics: Aminopyridines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Azacitidine; Cytogenetic Analysis; Decitabine; Enzyme Inhibitors; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunologic Factors; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Diagnostic Techniques; Neoplasm, Residual; Nivolumab; para-Aminobenzoates; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines; Recombinant Fusion Proteins; Remission Induction; Transplantation, Homologous; Triazines; Triazoles | 2019 |
New drugs approved for acute myeloid leukaemia in 2018.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Disease-Free Survival; Glycine; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Progression-Free Survival; Pyrazines; Pyridines; Remission Induction; Sulfonamides | 2019 |
Will new agents impact survival in AML?
Topics: Aniline Compounds; Disease-Free Survival; Drug Approval; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Pyrazines; Staurosporine; Survival Rate; United States | 2019 |
The growing landscape of FLT3 inhibition in AML.
Topics: Allografts; Aniline Compounds; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Middle Aged; Pyrazines; Staurosporine; Stem Cell Transplantation | 2019 |
FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Carbazoles; DNA Methylation; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mutation; Neoplasm Recurrence, Local; Phenylurea Compounds; Piperidines; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Sorafenib; Staurosporine; Treatment Outcome | 2020 |
Overcoming Resistance to FLT3 Inhibitors in the Treatment of
Topics: Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Drug Therapy, Combination; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrazines; Staurosporine | 2020 |
AML: New Drugs but New Challenges.
Topics: Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Pyrazines | 2020 |
The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an FLT3 Mutation.
Topics: Adult; Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Multicenter Studies as Topic; Mutation; Pyrazines | 2020 |
Gilteritinib: potent targeting of FLT3 mutations in AML.
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines | 2020 |
Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients.
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrazines | 2020 |
Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature.
Topics: Aged; Allografts; Anemia, Refractory, with Excess of Blasts; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Cytarabine; Daunorubicin; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Neoplasms, Radiation-Induced; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Salvage Therapy; Staurosporine; Sulfonamides | 2020 |
<Editors' Choice> How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement.
Topics: Aged; Aged, 80 and over; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Arsenic Trioxide; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; fms-Like Tyrosine Kinase 3; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Phenylurea Compounds; Precision Medicine; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Smoothened Receptor; Staurosporine; Sulfonamides; Survival Rate; Tretinoin; Triazines | 2020 |
Gilteritinib: A Review in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukaemia.
Topics: Aniline Compounds; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pyrazines | 2020 |
FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Carbazoles; Drug Resistance, Multiple; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Forecasting; Furans; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Mutation; Phenylurea Compounds; Piperidines; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Pyridazines; Recurrence; Sorafenib; Staurosporine | 2020 |
Midostaurin in acute myeloid leukemia: current evidence and practical considerations in routine clinical use.
Topics: Aniline Compounds; Anthracyclines; Antifungal Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Echinocandins; fms-Like Tyrosine Kinase 3; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Mutation; Mycoses; Protein Kinase Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Recurrence; Staurosporine; Triazoles | 2020 |
Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments.
Topics: Aniline Compounds; Antineoplastic Agents; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Pyrazines; Staurosporine | 2020 |
The safety profile of FLT3 inhibitors in the treatment of newly diagnosed or relapsed/refractory acute myeloid leukemia.
Topics: Aniline Compounds; Antineoplastic Agents; Benzothiazoles; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Staurosporine | 2021 |
Gilteritinib in the management of acute myeloid leukemia: Current evidence and future directions.
Topics: Adult; Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrazines | 2022 |
Gilteritinib in Isolated Breast Relapse of FLT3 Positive Acute Myeloid Leukemia: A Case Report and Review of Literature.
Topics: Aged; Aniline Compounds; Azacitidine; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Recurrence | 2022 |
10 trial(s) available for pyrazines and gilteritinib
Article | Year |
---|---|
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
Topics: Aged; Aniline Compounds; Antineoplastic Agents; Blood Platelets; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Phosphorylation; Pyrazines; Recurrence; Retreatment | 2017 |
Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open-label phase 1 study.
Topics: Aged; Aged, 80 and over; Aniline Compounds; Axl Receptor Tyrosine Kinase; Creatine Kinase; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Humans; Japan; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrazines; Receptor Protein-Tyrosine Kinases; Thrombocytopenia; Treatment Outcome | 2018 |
Gilteritinib or Chemotherapy for Relapsed or Refractory
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Liver; Male; Middle Aged; Mutation; Pyrazines; Recurrence; Remission Induction; Salvage Therapy; Survival Analysis | 2019 |
Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor.
Topics: Aniline Compounds; Drug Interactions; Female; Humans; Male; Protein Kinase Inhibitors; Pyrazines | 2020 |
Improved outcomes of octogenarians and nonagenarians with acute myeloid leukemia in the era of novel therapies.
Topics: Aged, 80 and over; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cyclopentanes; Disease-Free Survival; Female; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Pyrazines; Pyridines; Pyrimidines; Retrospective Studies; Sulfonamides; Survival Rate | 2020 |
Gilteritinib Plus Azacitidine Combination Shows Promise in Newly Diagnosed FLT3-Mutated AML.
Topics: Aniline Compounds; Azacitidine; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines | 2021 |
FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Posterior Leukoencephalopathy Syndrome; Pyrazines | 2021 |
Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Recurrence | 2022 |
Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib.
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Pyrazines | 2022 |
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Leukemia, Myeloid, Acute; Pyrazines | 2022 |
66 other study(ies) available for pyrazines and gilteritinib
Article | Year |
---|---|
Preliminary data on ASP2215: tolerability and efficacy in acute myeloid leukemia patients.
Topics: Aniline Compounds; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrazines; Receptor Protein-Tyrosine Kinases; Treatment Outcome | 2015 |
Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor.
Topics: Aniline Compounds; Cell Line, Tumor; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Pyrazines | 2017 |
Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Cell Line, Tumor; Disease Models, Animal; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Mutation; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrazines; Receptor Protein-Tyrosine Kinases; Xenograft Model Antitumor Assays | 2017 |
First new drug approval for AML in 15 years.
Topics: Aminoglycosides; Aminopyridines; Aniline Compounds; Antibodies, Monoclonal, Humanized; Drug Approval; fms-Like Tyrosine Kinase 3; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Staurosporine; Triazines | 2017 |
Closing in on targeted therapy for acute myeloid leukaemia.
Topics: Aniline Compounds; Antineoplastic Agents; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Pyrazines; Staurosporine | 2019 |
Discovery of a potent tyrosine kinase AXL inhibitor bearing the 3-((2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)amino)pyrazine core.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Benzazepines; Cell Line, Tumor; Drug Discovery; Mice; Molecular Structure; Protein Kinase Inhibitors; Pyrazines; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases | 2019 |
Gilteritinib induces differentiation in relapsed and refractory
Topics: Aniline Compounds; Cell Differentiation; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Pyrazines; Recurrence | 2019 |
Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Cell Line, Tumor; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Hematologic Neoplasms; Humans; Mutant Proteins; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-cbl; Proto-Oncogene Proteins c-kit; Pyrazines; Pyrazoles; Pyrroles; Sorafenib; Staurosporine; Triazines | 2019 |
Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
Topics: Aniline Compounds; Animals; Apoptosis; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; fms-Like Tyrosine Kinase 3; Gene Duplication; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Mice; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Staurosporine; Sulfonamides; Xenograft Model Antitumor Assays | 2019 |
Gilteritinib Changes AML Landscape.
Topics: Aniline Compounds; Clinical Trials, Phase III as Topic; Drug Approval; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrazines; Salvage Therapy; Survival Rate; Treatment Outcome | 2019 |
Improving Response to FLT3 Inhibitors-BCL2 the Rescue?
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Staurosporine | 2019 |
Successful treatment with gilteritinib for initially FMS-like tyrosine kinase 3 gene internal tandem duplications-positive elderly refractory acute myeloid leukemia that changed into FMS-like tyrosine kinase 3 gene tyrosine kinase domain-positive after co
Topics: Aged; Aniline Compounds; Antineoplastic Agents; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Protein Kinase Inhibitors; Pyrazines | 2019 |
Gilteritinib improves outcomes in AML.
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Pyrazines | 2020 |
How I treat acute myeloid leukemia in the era of new drugs.
Topics: Adult; Aged; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Mutation; Prognosis; Pyrazines; Pyridines; Sialic Acid Binding Ig-like Lectin 3; Staurosporine; Sulfonamides; Triazines | 2020 |
Erythroid differentiation of myeloblast induced by gilteritinib in relapsed FLT3-ITD-positive acute myeloid leukemia.
Topics: Aniline Compounds; Granulocyte Precursor Cells; Humans; Leukemia, Myeloid, Acute; Pyrazines | 2019 |
Gilteritinib induces PUMA-dependent apoptotic cell death via AKT/GSK-3β/NF-κB pathway in colorectal cancer cells.
Topics: Aniline Compounds; Animals; Apoptosis; Apoptosis Regulatory Proteins; Cell Death; Cell Line; Cell Line, Tumor; Colorectal Neoplasms; Female; Glycogen Synthase Kinase 3 beta; HCT116 Cells; HEK293 Cells; Humans; Mice; Mice, Nude; NF-kappa B; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction; Xenograft Model Antitumor Assays | 2020 |
Petromurin C Induces Protective Autophagy and Apoptosis in FLT3-ITD-Positive AML: Synergy with Gilteritinib.
Topics: Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aquatic Organisms; Autophagy; Biological Products; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Pyrazines; Signal Transduction; U937 Cells; Zebrafish | 2020 |
Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Benzimidazoles; Benzothiazoles; Cell Line, Tumor; Cell Proliferation; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Mice; Mutation; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazines; Sorafenib; Staurosporine; Syk Kinase | 2020 |
Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations.
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Mutation; Protein Kinase Inhibitors; Pyrazines | 2020 |
An Iridociliochoroidal Myeloid Sarcoma Associated With Relapsed Acute Myeloid Leukemia With FLT3-ITD Mutation, Treated With Gilteritinib, an FLT3 Inhibitor.
Topics: Administration, Oral; Aniline Compounds; Ciliary Body; Fatal Outcome; fms-Like Tyrosine Kinase 3; Humans; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrazines; Sarcoma, Myeloid; Uveal Neoplasms; Visual Acuity | 2020 |
Successful treatment with gilteritinib for isolated extramedullary relapse of acute myeloid leukemia with FLT3-ITD mutation after allogeneic stem cell transplantation.
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Pyrazines; Tandem Repeat Sequences; Transplantation, Homologous; Treatment Outcome | 2020 |
Durable remission of post-transplant relapsed FLT3-ITD AML in response to gilteritinib administration after a second transplant from the same donor.
Topics: Aniline Compounds; Female; fms-Like Tyrosine Kinase 3; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Recurrence; Remission Induction; Reoperation; Tandem Repeat Sequences; Tissue Donors; Treatment Outcome | 2020 |
Induction of leukemic stem cell differentiation by aryl hydrocarbon receptor agonist and synergy with gilteritinib in FLT3-ITD + acute myeloid leukemia.
Topics: Aniline Compounds; Cell Differentiation; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Receptors, Aryl Hydrocarbon | 2020 |
[Gilteritinib for pediatric FLT3 internal tandem duplication-positive recurrent acute myeloid leukemia].
Topics: Aniline Compounds; Child; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Pyrazines; Recurrence | 2020 |
An LC-MS/MS Bioanalytical Assay for the Determination of Gilteritinib in Rat Plasma and Application to a Drug-Drug Interaction Study.
Topics: Administration, Oral; Aniline Compounds; Animals; Chromatography, High Pressure Liquid; Drug Interactions; Fluconazole; Itraconazole; Male; Pyrazines; Rats; Rats, Sprague-Dawley; Tandem Mass Spectrometry | 2020 |
Successful remission induction therapy with gilteritinib in a patient with de novo FLT3-mutated acute myeloid leukaemia and severe COVID-19.
Topics: Adult; Aniline Compounds; COVID-19; COVID-19 Drug Treatment; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Pyrazines; Remission Induction; SARS-CoV-2 | 2020 |
Acute Macular Neuroretinopathy Associated With an Oral FLT3 Inhibitor.
Topics: Administration, Oral; Adult; Aniline Compounds; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Macula Lutea; Pyrazines; Tomography, Optical Coherence; White Dot Syndromes | 2020 |
Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a
Topics: Aniline Compounds; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Mutation; Prognosis; Protein Kinase Inhibitors; Pyrazines; Recurrence; Retreatment; Treatment Outcome | 2021 |
Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; CRISPR-Cas Systems; Female; fms-Like Tyrosine Kinase 3; Gene Knockout Techniques; Genetic Therapy; Humans; Leukemia, Myeloid, Acute; Mice, SCID; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Staurosporine; Sulfonamides | 2020 |
Gilteritinib administration in a hemodialysis patient.
Topics: Aged; Aniline Compounds; Female; Humans; Kidney Failure, Chronic; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrazines; Recurrence; Renal Dialysis | 2021 |
Successful bridge therapy of gilteritinib to cord blood transplantation in relapsed acute myeloid leukemia after bone marrow transplantation.
Topics: Adult; Aniline Compounds; Bone Marrow Transplantation; Cord Blood Stem Cell Transplantation; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Pyrazines | 2021 |
[Pharmacological and clinical profile of gilteritinib (Xospata
Topics: Adult; Aniline Compounds; Animals; fms-Like Tyrosine Kinase 3; Humans; Japan; Leukemia, Myeloid, Acute; Mice; Mutation; Pyrazines; Tablets; United States | 2021 |
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.
Topics: Aminopyridines; Aniline Compounds; Animals; Apoptosis; Benzamides; Carbazoles; Cell Line; Cell Survival; Crizotinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Immunoblotting; Indazoles; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mice, Inbred BALB C; Molecular Dynamics Simulation; Neoplasm Recurrence, Local; Piperidines; Proto-Oncogene Proteins; Pyrazines; Pyrazoles; Receptor Protein-Tyrosine Kinases | 2021 |
Myelomonocytic differentiation of leukemic blasts accompanied by differentiation syndrome in a case of
Topics: Adolescent; Aniline Compounds; Biopsy; Blast Crisis; Bone Marrow; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Leukemia, Myeloid, Acute; Male; Monocytes; Protein Kinase Inhibitors; Pyrazines; Radiography, Thoracic; Tandem Repeat Sequences | 2021 |
A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance.
Topics: Aniline Compounds; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Models, Molecular; Mutation; Protein Kinase Inhibitors; Pyrazines | 2021 |
A case report of combined treatment of gilteritinib and LH-RH agonist for Fms-related tyrosine kinase 3 receptor mutation-positive acute myeloid leukemia and bone marrow metastasis of prostate cancer.
Topics: Aniline Compounds; Bone Marrow Neoplasms; fms-Like Tyrosine Kinase 3; Gonadotropin-Releasing Hormone; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Oligopeptides; Prostatic Neoplasms; Pyrazines | 2022 |
Triazole antifungal use for prophylaxis and treatment of invasive fungal diseases for patients receiving gilteritinib.
Topics: Adult; Aged; Aged, 80 and over; Aniline Compounds; Antifungal Agents; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycoses; Prognosis; Pyrazines; Retrospective Studies; Survival Rate; Triazoles; Young Adult | 2021 |
The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML.
Topics: Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, Transgenic; Morpholines; Pyrazines; Pyrimidines; THP-1 Cells; Xenograft Model Antitumor Assays | 2021 |
The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance.
Topics: Aniline Compounds; Aurora Kinase B; Biomarkers, Tumor; Drug Resistance, Neoplasm; Exome; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Metabolome; Protein Kinase Inhibitors; Proteome; Pyrazines; Tumor Cells, Cultured; Tumor Microenvironment | 2021 |
Pediatric acute myeloid leukemia co-expressing FLT3/ITD and NUP98/NSD1 treated with gilteritinib plus allogenic peripheral blood stem cell transplantation: A case report.
Topics: Aniline Compounds; Child; fms-Like Tyrosine Kinase 3; Histone-Lysine N-Methyltransferase; Humans; Leukemia, Myeloid, Acute; Mutation; Nuclear Pore Complex Proteins; Peripheral Blood Stem Cell Transplantation; Pyrazines | 2021 |
Development, validation, and application of an LC-MS/MS method for the determination of the AXL/FLT3 inhibitor gilteritinib in mouse plasma.
Topics: Aniline Compounds; Animals; Chromatography, Liquid; Female; HEK293 Cells; Humans; Limit of Detection; Linear Models; Mice; Pyrazines; Reproducibility of Results; Tandem Mass Spectrometry | 2021 |
Dual Inhibition of FLT3 and AXL by Gilteritinib Overcomes Hematopoietic Niche-Driven Resistance Mechanisms in
Topics: Aniline Compounds; Axl Receptor Tyrosine Kinase; Benzothiazoles; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Proto-Oncogene Proteins; Pyrazines; Receptor Protein-Tyrosine Kinases | 2021 |
A Relapsing Meningeal Acute Myeloid Leukaemia FLT3-ITD+ Responding to Gilteritinib.
Topics: Aniline Compounds; Bone Marrow; Brain; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrazines; Treatment Outcome | 2021 |
Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia.
Topics: Aniline Compounds; Child; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Pyrazines | 2021 |
Gilteritinib-induced upregulation of S100A9 is mediated through BCL6 in acute myeloid leukemia.
Topics: Aniline Compounds; Humans; Leukemia, Myeloid, Acute; Proto-Oncogene Proteins c-bcl-6; Pyrazines; Up-Regulation | 2021 |
Gilteritinib vs salvage chemotherapy in FLT3-mutated acute myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial.
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Salvage Therapy | 2022 |
Bemcentinib and Gilteritinib Inhibit Cell Growth and Impair the Endo-Lysosomal and Autophagy Systems in an AXL-Independent Manner.
Topics: Aniline Compounds; Autophagy; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Cell Line, Tumor; Cell Proliferation; Humans; Lysosomes; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrazines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Transfection; Triazoles | 2022 |
What to use to treat AML: the role of emerging therapies.
Topics: Aged; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Approval; Drug Discovery; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Pyrazines; Pyridines; Triazines | 2021 |
[Successful treatment with gilteritinib for relapsed acute myeloid leukemia with FLT3-N676K mutation].
Topics: Aged; Aniline Compounds; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines | 2022 |
Development and Validation of an LC-MS/MS Method to Quantify Gilteritinib and Its Clinical Application in Patients With FLT3 Mutation-Positive Acute Myelogenous Leukemia.
Topics: Aniline Compounds; Chromatography, High Pressure Liquid; Chromatography, Liquid; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Limit of Detection; Mutation; Pyrazines; Reproducibility of Results; Tandem Mass Spectrometry | 2022 |
A novel approach for relapsed/refractory FLT3
Topics: Aniline Compounds; Animals; Disease Models, Animal; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mice; Mutation; NF-kappa B p52 Subunit; NK Cell Lectin-Like Receptor Subfamily K; Protein Kinase Inhibitors; Pyrazines; T-Lymphocytes | 2022 |
Interim results from a postmarketing surveillance study of patients with FLT3-mutated relapsed/refractory AML treated with the FLT3 inhibitor gilteritinib in Japan.
Topics: Aniline Compounds; Drug-Related Side Effects and Adverse Reactions; Female; fms-Like Tyrosine Kinase 3; Humans; Japan; Leukemia, Myeloid, Acute; Male; Mutation; Posterior Leukoencephalopathy Syndrome; Protein Kinase Inhibitors; Pyrazines | 2022 |
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrazines; Retrospective Studies; Sorafenib; Staurosporine | 2022 |
Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis.
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrazines | 2022 |
An Indirect Competitive Enzyme-Linked Immunosorbent Assay for the Determination of Brigatinib and Gilteritinib Using a Specific Polyclonal Antibody.
Topics: Aniline Compounds; Animals; Antibodies; Enzyme-Linked Immunosorbent Assay; Mice; Organophosphorus Compounds; Pyrazines; Pyrimidines; Rats | 2022 |
BMX kinase mediates gilteritinib resistance in FLT3-mutated AML through microenvironmental factors.
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein-Tyrosine Kinases; Pyrazines; Tumor Microenvironment | 2022 |
Understanding gilteritinib resistance to FLT3-F691L mutation through an integrated computational strategy.
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrazines | 2022 |
Epigenetic activation of the FLT3 gene by ZNF384 fusion confers a therapeutic susceptibility in acute lymphoblastic leukemia.
Topics: Aniline Compounds; Epigenesis, Genetic; fms-Like Tyrosine Kinase 3; Gene Fusion; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Trans-Activators; Transcription Factors | 2022 |
Real-world analysis of the safety/tolerability of gilteritinib in combination with mold-active azole prophylaxis.
Topics: Aniline Compounds; Azoles; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Pyrazines | 2022 |
Smith CC, Levis MJ, Perl AE, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155.
Topics: Aniline Compounds; Clinical Trials, Phase III as Topic; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Pyrazines | 2022 |
Posttransplant gilteritinib maintenance therapy for pediatric acute myeloid leukemia with myelodysplasia-related changes with FLT3-internal tandem duplication.
Topics: Aniline Compounds; Child; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines | 2023 |
Second relapse of FLT3-ITD-positive acute myeloid leukemia after discontinuation of 3-year post-transplant maintenance therapy with gilteritinib.
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Recurrence | 2023 |
Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R/R FLT3mut AML.
Topics: Aniline Compounds; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Pyrazines | 2023 |
Favorable pharmacokinetic and pharmacodynamic properties of gilteritinib in cerebrospinal fluid: a potential effective treatment in relapsing meningeal acute myeloid leukemia
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Treatment Outcome | 2023 |
Emergence of
Topics: Aniline Compounds; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Pyrazines | 2023 |
Gilteritinib-induced severe immune-related enteritis: a possible case report.
Topics: Aniline Compounds; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines | 2023 |